Alpha-6-alpha-4-beta-2-beta-3 nicotinic acetylcholine receptor (α6α4β2β3 nAChR)

The Alpha-6-alpha-4-beta-2-beta-3 nicotinic acetylcholine receptor is a specific heteropentameric subtype of ligand-gated ion channels found primarily in the dopaminergic neurons of the substantia nigra and ventral tegmental area (Gotti et al., 2009, PMID: 19190618). This receptor complex is composed of alpha-6, alpha-4, beta-2, and beta-3 subunits, which together form a high-affinity site for nicotine and acetylcholine, regulating the release of dopamine in the striatum (Salminen et al., 2007, PMID: 17110554). Its localized expression makes it a highly specific target for treating neurological and psychiatric conditions without the widespread side effects associated with more ubiquitous nicotinic subtypes. In the context of disease, this receptor is heavily implicated in the pathology of Parkinson's disease, where alpha-6-containing receptors are among the first to be lost as dopaminergic neurons degenerate (Quik et al., 2011, PMID: 21661054). Additionally, it plays a central role in the reinforcing properties of nicotine, making it a primary focus for smoking cessation therapies and the treatment of nicotine addiction (Yang et al., 2011, PMID: 21953150). Pharmacological agents such as varenicline and selective alpha-6 antagonists are used or being researched to modulate this receptor's activity to restore dopaminergic balance or curb addictive behaviors. However, the high structural similarity between various nicotinic acetylcholine receptor (nAChR) subtypes poses a challenge for achieving high selectivity and avoiding peripheral side effects such as cardiovascular or gastrointestinal issues.

Other names

Alpha-6-alpha-4-beta-2-beta-3 nicotinic receptorα6α4β2β3 nicotinic acetylcholine receptorAlpha-6-containing nicotinic acetylcholine receptorα6β2* nAChRCHRNA6-CHRNA4-CHRNB2-CHRNB3 complex

Agonism or antagonism of the ligand-gated ion channel to modulate the influx of sodium and calcium ions, thereby regulating neuronal excitability and the release of neurotransmitters, specifically dopamine (Gotti et al., 2009, PMID: 19190618).